Iovance Biotherapeutics, Inc.
IOVA
$3.78
-$0.10-2.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -17.68% | 28.64% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -17.68% | 28.64% | |||
| Cost of Revenue | -1.42% | 12.04% | |||
| Gross Profit | -33.73% | 50.67% | |||
| SG&A Expenses | 7.00% | 5.34% | |||
| Depreciation & Amortization | -10.28% | 5.66% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.84% | 1.92% | |||
| Operating Income | -10.32% | 18.16% | |||
| Income Before Tax | -11.14% | 23.42% | |||
| Income Tax Expenses | -461.41% | 107.65% | |||
| Earnings from Continuing Operations | -9.93% | 21.20% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -9.93% | 21.20% | |||
| EBIT | -10.32% | 18.16% | |||
| EBITDA | -14.12% | 21.57% | |||
| EPS Basic | -6.90% | 29.52% | |||
| Normalized Basic EPS | -7.58% | 26.18% | |||
| EPS Diluted | -6.90% | 29.52% | |||
| Normalized Diluted EPS | -7.58% | 26.18% | |||
| Average Basic Shares Outstanding | 2.84% | 11.79% | |||
| Average Diluted Shares Outstanding | 2.84% | 11.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||